Repligen (RGEN)
(Delayed Data from NSDQ)
$145.78 USD
-2.76 (-1.86%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $145.80 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
Repligen Corporation [RGEN]
Reports for Purchase
Showing records 161 - 180 ( 205 total )
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Solid in the Face of Adversity; Reiterate Buy; Modulating Target to $100
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
2Q19 Financial Results Reported; Top- and Bottom-Line Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Financing Transactions Indicate Investor Demand; Long-Term Projections Improved; Upgrading to Buy With $110 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
FY2018 Financial Results Reported; Record Revenue With Earnings Slightly Ahead of Projections; Raising Target to $65
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
3Q18 Results Reported; Still an Expensive Stock; Reiterate Neutral and Raising Target to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Welsh Agarose Plant Opens on Schedule; Estimates Revised; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Pricey But Built to Last; Initiating at Neutral and $49 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
Company: Repligen Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of June 17This report contains brief updates on the following: PCYC, LGND, ONXX, RGEN, ANAC, ARNA, ONCY, CRDC. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L